0000899243-20-028184.txt : 20201014 0000899243-20-028184.hdr.sgml : 20201014 20201014163008 ACCESSION NUMBER: 0000899243-20-028184 CONFORMED SUBMISSION TYPE: 3/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200729 FILED AS OF DATE: 20201014 DATE AS OF CHANGE: 20201014 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Miller Edward CENTRAL INDEX KEY: 0001619252 FILING VALUES: FORM TYPE: 3/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-39409 FILM NUMBER: 201239308 MAIL ADDRESS: STREET 1: C/O ALEXION PHARMACEUTICALS, INC STREET 2: 352 KNOTTER DRIVE CITY: CHESHIRE STATE: CT ZIP: 06410 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Allovir, Inc. CENTRAL INDEX KEY: 0001754068 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 831971007 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 139 MAIN STREET, SUITE 500 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (617) 433-2605 MAIL ADDRESS: STREET 1: 139 MAIN STREET, SUITE 500 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: ViraCyte, Inc. DATE OF NAME CHANGE: 20180924 3/A 1 doc3a.xml FORM 3/A SUBMISSION X0206 3/A 2020-07-29 2020-07-30 0 0001754068 Allovir, Inc. ALVR 0001619252 Miller Edward C/O ALLOVIR, INC. 139 MAIN STREET, SUITE 500 CAMBRIDGE MA 02142 0 1 0 0 General Counsel Common Stock 207565 D Common Stock 124538 I By Trust This amendment on Form 3/A to the Form 3 originally filed on July 30, 2020 (the "Original Form 3") is being filed solely to include 124,538 shares of Common Stock held indirectly by the Reporting Person's trust, which were incorrectly reported as directly held by the Reporting Person on the Original Form 3. This amendment does not impact the Reporting Person's Table II holdings as reported in the Original Form 3. Shares held by The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. /s/ Edward Miller 2020-10-14